Oxolife Appoints International Fertility Experts to its Scientific Advisory Board

Oxolife, the specialized biotech focused on enhancing embryo implantation in women undergoing Assisted Reproductive Technology (ART) fertility treatment, today announces it has appointed globally renowned fertility experts to its Scientific Advisory Board (SAB).

There is a very large and growing global infertility market, with 76 million women affected each year – approximately 2% of the global female population. With approximately three million assisted reproductive technology cycles each year, of which 50% fail, there is a significant unmet medical problem. More than 30% of procedures fail due to implantation issues, the causes of which are largely unknown, and for which there are no treatment options.

Oxolife is developing a novel, easy-to-administer, non-hormonal, oral pill that boosts endometrial adhesion and invasion of the embryo, a major factor in improving pregnancy success rates. The SAB includes world-leading experts in the fertility field who are involved in the clinical management at some of the top global reproductive clinics and research centers. They have a track record of nearly 1,200 fertility and reproduction-related publications. The SAB will be instrumental in advancing the development of OXO-001.

Juan García-Velasco, Chief Scientific Officer of IVIRMA and Chair of the Scientific Advisory Board of Oxolife, commented: “Millions of women undergo assisted reproductive technology cycles each year, with many of these cycles failing, and with no treatment options, it can be a very challenging time. We are very pleased to support the development of this innovative therapy which offers the potential to help millions of women worldwide conceive.

Agnès Arbat, Chief Executive Officer and Chief Medical Officer of Oxolife said: “Oxolife’s vision is to develop the first treatment that improves embryo implantation, a major factor in improving pregnancy success rates for women undergoing Assisted Reproductive Technology treatment. The experience and track record of this leading international Scientific Advisory Board will be invaluable in supporting our plans to accelerate the development of OXO-001.

Scientific Advisory Board

Professor Juan García-Velasco - Chair

Professor Garcia-Velasco is Chief Scientific Officer at IVIRMA Global and a Director of IVI Madrid, in addition to being a professor of Obstetrics & Gynecology at Rey Juan Carlos University, Madrid, and a Director of the Master’s Degree program in Human Reproduction.

He has more than 220 peer-reviewed articles and 31 book chapters on human reproduction published, alongside being an editor of Reproductive BioMedicine Online and Principal Investigator of projects funded by the Ministry of Education and Health of Spain. He has also received awards from the Spanish Fertility Society, Spanish Society of Gynecology and Obstetrics, and the European Society of Human Reproduction and Embryology.

Professor Baris Ata

Professor Ata is an IVF Specialist at ART Fertility Clinics, Dubai, UAE, and a Professor of Obstetrics and Gynecology at Koç University School of Medicine, Istanbul. He was an Executive Committee Member of the European Society of Human Reproduction and Embryology and is the President of the Turkish Society of Reproductive Medicine. With more than 150 publications in leading journals and a member of editorial boards of renowned scientific journals, such as Human Reproduction Update, Human Reproduction, Reproductive BioMedicine Online, among others, Baris is a trained clinical researcher and has a wealth of experience in the field of fertility and reproductive medicine. He holds multiple awards for research, education, and clinical excellence from national and international institutions.

Professor Shari Mackens

Professor Mackens is the Medical Director at Brussels IVF and a Clinical Professor at the Vrije Universiteit Brussel (VUB) with over 11 years of basic science research on endometrial receptivity and human embryo implantation. She has authored 44 publications in peer-reviewed international journals and lectures, and is an Editor for Reproductive BioMedicine Online.

Professor Scot Nelson

Professor Nelson is Muirhead Professor of Obstetrics & Gynecology at the University of Glasgow and a Consultant for NHS Greater Glasgow and Clyde. He is also the Medical Director of Access Fertility, Scientific Director of The Fertility Partnership, and has authored over 227 scientific articles and book chapters. He has received grants from the National Institute of Health, the Medical Research Council, and Scottish Health Department, among others, and received awards from the European Society of Human Reproduction and Embryology.

Professor Georg Griesinger

Professor Griesinger is Chair at the Department of Gynecological, Endocrinology, and Reproductive Medicine at the University Hospital of Schleswig-Holstein, Luebeck, Germany, and Professor at Luebeck University. He has been a Board member of the European Society of Human Reproduction and Embryology since 2013 and a member of the WHO infertility guidelines group. He has authored more than 120 scientific articles, reviews, and book contributions and has been the main author for Nolasiban (ObsEVA) publications and Editor of several national and international scientific journals.

Professor Anja Pinborg

Professor Pinborg is Medical Director and Professor at the Fertility Department at Rigshospitalet, Copenhagen University Hospital. She has been an ESHRE Executive Committee member until 2021, in addition to previously being Chair of the Nordic Fertility Society. She is the deputy editor of Human Reproduction Open.

• By Oxolife
• 13/11/2023
• Oxolife